This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.


This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.


This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

Flat and stable

Flat and stable glucose-lowering effect with an ultra-long duration of action beyond 42 hours
Hypo reduction

Consistent hypo reduction vs glargine U100 and glargine U300*
Time in range

Increase in Time in Range vs glargine U100 in patients with type 2 diabetes

The Tresiba® label now includes controlled clinical trial data on its use in pregnant women with diabetes+1**

  • Reducing insulin doses17
  • Skipping injections17
  • Avoiding physical exercise17

Although the fear of hypos is a barrier to insulin adherence for almost 9 out of 10 patients,15 it is possible to achieve good control with a low risk of hypoglycaemia.5,6


Indeed, when it is time to consider insulin for a patient with type 2 diabetes, the consensus of the ADA and the EASD is to choose a basal insulin with a low risk of hypoglycaemia.18


Download consensus report

* Real-world evidence studies.

† (p=0.002).4

Data from the extension trial set.4

In the BEGIN Once long trial, in insulin-naïve patients with type 2 diabetes, confirmed hypoglycaemic episodes included either episodes confirmed by self-monitored blood glucose corresponding to plasma glucose value <3.1 mmol/L (<56 mg/dL) or severe episodes requiring assistance. Episodes occurring between  00:01 and 05:59 (both inclusive) were classified as nocturnal.4

‡ (p<0.001). Maintenance period.5

In the SWITCH 2 trial, in patients with type 2 diabetes, overall hypoglycaemia  was defined as severe or BG-confirmed (<3.1 mmol/L [<56 mg/dL]) with  symptoms, and severe hypoglycaemia was defined as an episode requiring  assistance of another person to actively administer carbohydrate, glucagon, or  take other corrective actions, neurological recovery following the return of  plasma glucose to normal, or both (ADA definition).5

§ (p<0.001).6

In the DEVOTE trial, in patients with type 2 diabetes at high risk of CV events,  severe hypoglycaemic episodes were independently adjudicated using the ADA  definition.6

¶ (p<0.05).7

CONFIRM was a retrospective real-world study.7

In the CONFIRM study, in insulin-naïve patients with type 2 diabetes,  hypoglycaemia was recorded by the treating clinician and defined according to  International Classification of Diseases codes 9 and 10.7

ǁ (p<0.001).8

ReFLeCT was a prospective real-world study.8

In the ReFleCT study, in patients with type 2 diabetes, overall hypoglycaemia  was defined as any event recorded as hypoglycaemia in patients’ diaries  irrespective of symptoms, blood glucose or time of day.8

ADA (American Diabetes Association). BG (blood glucose). CV (cardiovascular).


Tresiba® (Summary of Product Characteristics). Bagsværd, Denmark: Novo Nordisk A/S; January 2022.


Vora J, Heise T. Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review. Diabetes, Obesity & Metabolism 2013; 15(8):701-712.


Haahr H, Heise T. A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance. Clinical Pharmacokinetics 2014; 53(9):787-800.


Rodbard HW, Cariou B, Zinman B, Handelsman Y, Philis-Tsimikas A, Skjøth TV, Rana A, Mathieu C on behalf of the BEGIN Once Long Trial Investigators. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial. Diabetic Medicine 2013; 30(11):1298-1304.


Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen L, Kvist K, Norwood P. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: The SWITCH 2 Randomized Clinical Trial. JAMA 2017; 318(1):45-56.


Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr P-M, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB for the DEVOTE Study Group. Efficacy and safety of degludec versus glargine in type 2 diabetes. New England Journal of Medicine 2017; 377(8):723-732.


Tibaldi J, Hadley-Brown M, Liebl A, Haldrup S, Sandberg V, Wolden ML, Rodbard HW. A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2019; 21:1001-1009.


Fadini GP, Feher M, Hansen TK, de Valk HW, Koefoed MM, Wolden M, Zimmermann E, Jendle J. Switching to degludec from other basal insulins is associated with reduced hypoglycemia rates: a prospective study. Journal of Clinical Endocrinology and Metabolism 2019; 104(12):5977-5990.


Goldenberg RM, Aroda VR, Billings LK, Christiansen ASL, Donatsky AM, Rizi EP, Podgorski G, Raslova K, Klonoff DC, Bergenstal RM. Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia. Diabetes, Obesity and Metabolism 2021. doi: 10.1111/dom.14504.


Mathiesen ER et al. Maternal efficacy, safety, and pregnancy outcomes with degludec versus detemir in the treatment of pregnant women with type 1 diabetes: an international, multicentre, randomised trial. Presented at the European Association for the Study of Diabetes 57th Annual Meeting, 27 September-1 October 2021, Virtual Meeting.


Vora J, Cariou B, Evans M, Gross JL, Harris S, Landstedt-Hallin L, Mithal A, Rodriguez MR, Meneghini L. Clinical use of insulin degludec. Diabetes Research and Clinical Practice 2015; 109(1):19-31.


Heise T, Kaplan K, Haahr H. Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies. Journal of Diabetes Science and Technology 2018; 12(2):356-363.


Heise T, Nørskov M, Nosek L, Kaplan K, Famulla S, Haahr HL. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300U/mL in type 1 diabetes. Diabetes, Obesity & Metabolism 2017: 19(7):1032-1039.


Curtis B, Lage MJ. Glycemic control among patients with type 2 diabetes who initiate basal insulin: a retrospective cohort study. Journal of Medical Economics 2014; 17(1):21-31.


Farsaei S, Radfar M, Heydari Z, Abbasi F, Qorbani M. Insulin adherence in patients with diabetes: risk factors for injection omission. Primary Care Diabetes. 2014; 8(4):338-345.


Khunti K, Alsifri S, Aronson R, Cigrovski Berkovic´ M, Enters-Weijnen C, Forsén T, Galstyan G, Geelhoed-Duljvestijn P, Goldfracht M, Gydesen H, Kapur R, Lalic N, Ludvik B, Moberg E, Pedersen-Bjergaard U, Ramachandran A on behalf of the HAT Investigator Group. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. Diabetes, Obesity & Metabolism 2016; 18(9):907-915.


Khunti K, Alsifri S, Aronson R, Cigrovski Berkovic´ M, Enters-Weijnen C, Forsén T, Galstyan G, Geelhoed-Duljvestijn P, Goldfracht M, Gydesen H, Kapur R, Lalic N, Ludvik B, Moberg E, Pedersen-Bjergaard U, Ramachandran A on behalf of the HAT Investigator Group. Impact of hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people with type 1 and insulin-treated type 2 diabetes. Diabetes Research and Clinical Practice 2017; 130:121-129.


Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, D'Alessio DA, Davies MJ. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2020; 63(2):221-228. doi: 10.1007/s00125-019-05039-w.


Toujeo® Summary of Product Characteristics, November 2021


Levemir® Summary of Product Characteristics, April 2021


Levemir Prescribing Information Novo Nordisk, August 2022.